s, estimates or projections relating to the future, are forward-looking statements within the meaning of these laws. The Company's actual results may differ materially from those suggested as a result of various factors. Interested parties should refer to the disclosure concerning the operational and business concerns of the Company set forth in the Company's filings with the Securities and Exchange Commission.
(tables follow)
PRO-DEX, INC. and SUBSIDIARIES CONSOLIDATED BALANCE SHEETS June 30, 2012June 30, 2011ASSETSCurrent assets:Cash
$
4,112,000$ 4,689,000Accounts receivable, net of allowance for doubtful accounts of $16,000 and $7,000 at June 30, 2012 and 2011, respectively
1,581,0003,128,000Other current receivables
123,00012,000Inventories
2,791,0003,703,000Prepaid expenses
172,000145,000Income taxes receivable
609,000--Deferred income taxes
109,000163,000Total current assets
9,497,00011,840,000Property, plant, equipment and leasehold improvements, net
2,539,0003,661,000Real estate held for sale
733,000--Other assets
53,00060,000Total assets
$
2,822,000$ 15,561,000LIABILITIES AND SHAREHOLDERS' EQUITYCurrent liabilities:Accounts payable
$
33,000$ 1,207,000Accrued expenses
1,425,0002,379,000Income taxes payable
47,00078,000Current portion of bank term loan
774,000357,000Total current liabilities
2,879,0004,021,000Non-current liabilities:Bank term loan
--774,000Deferred income taxes
109,000163,000Deferred rent
284,000279,000Total non-current liabilities
393,0001,216,000Total liabilities
3,272,0005,237,000Commitments and contingenciesShareholders' equity:Common shares; no par value; 50,000,000 shares authorized; 3,272,350 shares issued and outstanding at June 30, 2012 and 2011
16,846,00016,744,000Accumulat
'/>"/>
SOURCE Pro-Dex, Inc. Copyright©2012 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 7 Related medicine technology :1.
Pro-Dex, Inc. Announces Fiscal 2012 Fourth Quarter and Full-Year Financial Results Conference Call and Webcast2.
Pro-Dex, Inc. Announces Update Conference Call and Webcast3.
Pro-Dex, Inc. Announces Fiscal Third Quarter and Nine Month Results4.
Pro-Dex, Inc. Announces Fiscal 2012 Third Quarter Financial Results Conference Call and Webcast5.
Pro-Dex, Inc. Appoints Michael J. Berthelot Chief Executive Officer6.
Catalent Pharma Solutions, Inc. Announces Cash Tender Offer for up to $250 Million of Its 9-1/2%/10-1/4% Senior PIK-Election Notes due 20157.
International Isotopes Inc. Announces Nuclear Regulatory Commission Approval Of The Final Environmental Impact Statement For The Planned Depleted Uranium De-Conversion And Fluorine Extraction Processing Facility8.
Avanir Pharmaceuticals Announces Enrollment Of First Patient In Study Of AVP-923 For The Treatment Of Agitation In Patients With Alzheimers Disease9.
Shield HealthCare Announces 12th Annual Caregiver Story Contest10.
West Announces Agreement with Janssen Biotech to Develop and Commercialize a New Self-injection Technology11.
Orexigen Therapeutics Announces Presentations at Upcoming Investor Conferences